Phase 2 N=55 Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
Carcinoma, Non Small Cell Lung
Primary: Recommended Phase 2 Dose (RP2D) - Phase 1 — 45 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty
Subjects Requesting and Requiring an Open Rhinoplasty
Primary: Edema Severity — 1.25; 1.5; 1.25; 1 units on a scale
Phase 2 N=28 Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
Posttraumatic Stress Disorder
Primary: Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session — -26.3; -24.4; -11.5…
Phase 2 N=9 M7824 in People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Respiratory Papillomatosis · Laryngeal Papilloma, Recurrent
Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants
Phase 2 N=149 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 24 — 18.4; 58.0 percentage of participants — p=<0.001
Phase 2 N=20 PSMA Imaging of Localized Prostate Cancer
Prostate Cancer
Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…
Phase 2 N=3 Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Hematopoietic and Lymphoid Cell Neoplasm · Locally Advanced Malignant Solid Neoplasm · Locally Advanced Melanoma
Primary: Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib. — 75 mg
Phase 2 N=216 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
Depression · Major Depressive Disorder · Dysthymic Disorder
Primary: Brachial Artery Flow-Mediated Dilation (FMD) at 12 Months — 2.28; 2.44 % increase in brachial diameter — p=0.60
Phase 2 N=199 Efficacy and Safety Study of Ozanimod in Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Who Achieved Clinical Remission Based on the Central Read of the Mayo Score (MS), at Week 8 — 6.2; 13.8; 16.4 Percentage of Participants…
Phase 2 N=91 A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
Keratoconjunctivitis Sicca
Primary: Inferior Corneal Fluorescein Staining — 2.40; 2.07; 2.11 units on a scale
Phase 2 N=12 Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
Social Anxiety in Autistic Adults
Primary: Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2 — 34.3; 55.5; 64.0 score on a scale
Phase 2 N=110 A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).
Asthma
Primary: Percentage of Participants With Asthma Exacerbations at Week 12 — 38.9; 25.0; 41.7; 38.9 percentage of participants — p=0.312
Phase 2 N=651 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
Smallpox
Primary: ELISA GMT — 875.1; 1099.6 Titer
Phase 2 N=12 Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants
Phase 2 N=720 Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
Avian Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies — 33.6; 33.5; 39.2; 5.5 titer